Novo Nordisk is trading 3.2% up at €44.10 in a rebound from recent weakness, outperforming a healthcare sector that is currently under pressure.
- The move comes despite a lack of fresh company-specific catalysts, as broad equity markets trade modestly higher.
- Shares have recently faced pressure from cautious 2026 guidance and U.S. pricing and coverage headwinds for obesity drugs and insulin.